To enable researchers from European institutes to extend innovative structural biology research, the EU has invested 10 million euro to iNEXT-Discovery, through its Horizon 2020 program.

The iNEXT-Discovery consortium, coordinated by Prof. Dr. Anastassis Perrakis from the Netherlands Cancer Institute and Oncode Institute, aims to facilitate the generation of knowledge for the development of new drugs, advanced vaccines, novel biomaterials, engineered enzymes for food production, efficient biofuels, and other benefits. iNEXT-Discovery will do this by enabling leading European facilities to offer advanced technological instrumentation and expertise to all European scientists, allowing them to perform high-end structural biology research with state-of-the-art equipment that is often unavailable in their home countries.

Advancing technologies beyond the state of the art

Joining forces within the iNEXT-Discovery consortium also enables the partners to collaborate in joint research activities that will allow new and better ways to perform structural biology experiments. iNEXT-Discovery will build on the expertise of the partners to: further consolidate the strong role of structural biology in drug development by developing fragment-based lead discovery; develop tools to increase the throughput for electron microscopy and serial X-ray crystallography; integrate structural biology technologies; push nuclear magnetic resonance (NMR) spectroscopy and other technologies to better describe time scales, molecular states and dynamics; and integrate structural biology approaches for imaging cells.

Enabling research without borders

iNEXT-Discovery includes partners from institutions outside of the facility providers that also collaborate on planned joint research projects. Prof. Dr. Anastassis Perrakis from the Division of Biochemistry at the NKI and Oncode Institute explains: “Together with regional experts, specifically from the Baltic and Balkan countries, and with five ESFRI communities in the fields of health, biotechnology, and food, we are offering cutting-edge technologies and novel experimental possibilities to all European scientists, enabling experiments that would be impossible without our facilities.” Integration will be further enabled through the extensive and inclusive training program that the iNEXT-Discovery has developed, and that will be deployed in the coming four years.

iNEXT-Discovery and the NKI

The NKI makes the Protein Facility, and specifically all instrumentation for the characterisation of macromolecular interactions, available. “At the Protein Facility, we have a collection of biophysical instruments and unique expertise, that allows us to approach different problems with different methodologies”, says Anastassis Perrakis. “Similar to iNEXT, we expect to welcome twenty user groups from all over Europe, and share our instruments and experience, contributing to exciting new science.”

How to access iNEXT-Discovery facilities
Access to all facilities will be available through an open peer review system that is based on scientific excellence and the potential of each project for enabling translational research. While iNEXT-Discovery expects Open Access publication from all users, it also enables researchers from industry to access its facilities as a fee-for-service, through a dedicated access portal. Starting from the 1st of February 2020, iNEXT-Discovery will be open for applications.

Structural Biology
Structural biology is of paramount importance for basic research in biochemistry, biomedicine and biotechnology, and key for fundamental innovations in health, environment and green economy. Structural biology unravels the 3D-structures of biological macromolecules, helping scientists to understand their roles within the intricate machinery of life, design new macromolecules with better properties for industry or for health, or develop small molecules that interfere with function and can be developed as the drugs of tomorrow. In the past and the present, Europe remains in a leading position in this research area.

About the Netherlands Cancer Institute

The Netherlands Cancer Institute is at the international forefront of cancer care and research for already more than a century. The unique combination of health care and scientific research within the same institute offers great benefit for cancer patients. Specialized cancer care professionals work together in multidisciplinary teams every day to set up and carry out treatment plans tailored to the needs of individual patients because no two tumors are alike. Cancer patients or people suspected of having cancer can come to our hospital, known as the Antoni van Leeuwenhoek, to make use of this personal approach and the state-of-the-art research and treatment facilities. The research institute employs more than 650 scientists investigating many aspects of cancer development, diagnosis, treatment and epidemiology. Scientists at the Netherlands Cancer Institute have access to state-of-the-art research facilities supporting their basic, translational and clinical research. This scientific research could not be carried out without the institutional support of the Dutch Cancer Society, the Ministry of Health, Welfare and Sport, the many research grants obtained by our researchers from (inter)national funding agencies, and the generous donations made by individuals that support our research program. The Netherlands Cancer Institute is the only OECI designated Comprehensive Cancer Center in the Netherlands.